

031804
15992 U.S. PTO

PTO/SB/05 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

<i>Attorney Docket No.</i>	29248/21
<i>First Inventor</i>	Erik Buntinx
<i>Title</i>	METHOD OF TREATING NEURODEGENERATIVE DISEASES.....
<i>Express Mail Label No.</i>	EL 996377277 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- | | |
|---|--|
| <p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17)
<i>(Submit an original and a duplicate for fee processing)</i></p> <p>2. <input type="checkbox"/> Applicant claims small entity status.
See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages <u>44</u>] <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none"> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix. - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure <p>4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u> </u>]</p> <p>5. Oath or Declaration [Total Sheets <u> </u>]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i></p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> | <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program <i>(Appendix)</i></p> <p>8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. <input type="checkbox"/> Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input type="checkbox"/> Paper</p> <p>c. <input type="checkbox"/> Statements verifying identity of above copies</p> |
|---|--|

ACCOMPANYING APPLICATION PARTS

- | |
|--|
| <p>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input checked="" type="checkbox"/> Other:Cover Letter.....</p> |
|--|

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:


Continuation Divisional Continuation-in-part (CIP) of prior application No.: 10/752,423.....

Prior application information: Examiner _____ Art Unit: _____
For CONTINUATION OF DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Customer Number: _____ OR Correspondence address below

Name	Alan D. Miller			
Address	AMSTER, ROTHSTEIN & EBENSTEIN LLP 90 Park Avenue			
City	New York	State	New York	Zip Code
Country	USA	Telephone	(212) 336-8000	Fax

Name (Print/Type)	Alan D. Miller	Registration No. (Attorney/Agent)	42,889
Signature			Date

March 18, 2004

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

17548 U.S. PTO
10/8/03793

031804

15992 U.S.PTO
031804

AMSTER ROTHSTEIN & EBENSTEIN LLP

Intellectual Property Law

90 Park Avenue
New York NY 10016
Main 212 336 8000
Fax 212 336 8001
Web www.arelaw.com

Partners

Morton Amster
Jesse Rothstein (1934 - 2003)
Daniel Ebenstein
Philip H. Gottfried
Michael J. Berger
Neil M. Zipkin
Anthony F. Lo Cicero
Kenneth P. George
Abraham Kasdan, Ph.D.
Ira E. Silfin
Chester Rothstein
Craig J. Arnold
Kenneth M. Bernstein

Senior Counsel

Charles R. Macedo
Mark J. Rosenberg
Nancy M. Dodderidge
Of Counsel
Jerry D. Dainow

Associates

Neal L. Rosenberg
Patrick Boland*
Trebor Lloyd
Joseph M. Casino
John S. Economou

Michael V. Solomita
Holly Pekowsky
Michael P. Kenney
Marion P. Metelski
Max Vern
Dana R. Metes
Karl J. Kolbinger
Brian A. Comack
Richard S. Mandaro
Marc J. Jason
Elie H. Gendloff, Ph.D.
David Mitnick
Charles W. Rath
David A. Boag

Karen J. Bernstein
Matthieu Hausig
Jung S. Hahn
Reiko Kaji
Alan D. Miller, Ph.D.
Hsin-Hsin (Ginger) Liu
John A. Lopore*
Norajean McCaffrey

*Not admitted in New York

March 18, 2004

Via Express Mail

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Alan D. Miller
Direct 212 336 8094
E-mail amiller@arelaw.com

"Express Mail" mailing label no.	EL 996377277 US
Date of Deposit:	March 18, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

Re: New U.S. Patent Application, Continuation-in-Part of
U.S. Patent Application No. 10/752,423, Continuation-
in-Part of U.S. Patent Application No. 10/725,965
Title: METHOD OF TREATING NEURODEGENERATIVE
DISEASES USING D4 AND 5-HT2A ANTAGONISTS,
INVERSE AGONISTS OR PARTIAL AGONISTS

Inventor: Erik Buntinx
Our File: 29248/21

Dear Sir:

Enclosed please find a Continuation-in-Part application in the name of Erik Buntinx, entitled METHOD OF TREATING NEURODEGENERATIVE DISEASES USING D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS, including the following:

1. a Utility Patent Application Transmittal sheet (Form PTO/SB/05);
2. a complete utility application, including specification (36 pages); claims (7 pages); abstract (1 page); and
3. a return receipt postcard.

This application is a Continuation-in-Part Application of U.S. Patent Application No. 10/752,423 filed January 6, 2004, which is a Continuation-in-Part of U.S. Application No. 10/725,965 filed December 2, 2003.

Commissioner for Patents

-2-

March 18, 2004


Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: March 18, 2004
New York, New York

By _____


Alan D. Miller, Reg. No. 42,889